TREATMENT OF HIV-ASSOCIATED HODGKIN'S DISEASE (HIV-HD): IS THERE A CLUE REGARDING THE ETIOLOGY OF HODGKIN'S DISEASE? (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


TREATMENT OF HIV-ASSOCIATED HODGKIN'S DISEASE (HIV-HD): IS THERE A CLUE REGARDING THE ETIOLOGY OF HODGKIN'S DISEASE? (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 11:A1 1992. Unique Identifier : AIDSLINE ICDB/92680732
Newcom S; Ward M; Napoli V; Kutner M; Emory Univ. Sch. of Medicine, Atlanta, GA

Abstract: Between 1983 and 1990, 25 patients (pts) with HIV-associated lymphomas were treated (8 with HIV-HD; 17 with HIV-NHL). The CR rate in HIV-HD was 100% with MOPP and ABVD (actuarial survival was 83% at 85 mo; median follow-up = 24+ mo; median survival = 38.0 +/- 9.52 mo). The number of cycles of chemotherapy received was 2-11 (median = 5.5). There was one late relapse which was successfully salvaged. Eleven HIV-NHL pts were treated with CHOP (CR = 80%, median survival = 13.0 +/- 6.22 mo). Durable CR was achieved with 1-6 cycles of chemotherapy (median = 4). There were no late relapses. The difference between the survival of chemotherapy-treated HIV-HD and chemotherapy-treated HIV-NHL was significant (p = 0.03). Analysis indicated that no HIV-HD pt had the nodular sclerosis histologic subtype and all pts (8/8) acquired HIV through iv drug abuse (IVDA) compared to 1/17 HIV/NHL pts (p less than 0.005). The CD4-positive lymphocyte counts (307 vs 231) and absolute lymphocyte counts (2284 vs 1639) tended to be higher in the HIV-HD pts (p less than 0.1). A meta-analysis identified 51 histologically confirmed chemotherapy-treated HIV-HD pts (median survival = 20.0 +/- 5.38 mo) vs 151 chemotherapy-treated HIV-NHL pts (median survival = 9.0 +/- 0.81 mo; p=0.0001). The meta-analysis confirmed that IVDA was associated with 76% of HIV-HD. These results show that standard chemotherapy regimens (truncated as necessary) are effective for inducing a durable CR in HIV-HD and HIV-NHL. HIV-HD has a significantly better prognosis than HIV-NHL and is usually associated with IVDA suggesting that etiologic differences between HIV-HD and HIV-NHL may be identifiable.
Keywords: Antineoplastic Agents, Combined/*THERAPEUTIC USE Bleomycin/ADMINISTRATION & DOSAGE Comparative Study Dacarbazine/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION & DOSAGE Follow-Up Studies Hodgkin's Disease/*DRUG THERAPY/*ETIOLOGY/PATHOLOGY Human HIV Infections/*COMPLICATIONS Mechlorethamine/ADMINISTRATION & DOSAGE Meta-Analysis Prednisone/ADMINISTRATION & DOSAGE Procarbazine/ADMINISTRATION & DOSAGE Substance Dependence Time Factors Vincristine/ADMINISTRATION & DOSAGE CLINICAL TRIAL ABSTRACT META-ANALYSIS

KWDantineoplasticagents,combined/KWDtherapeuticusebleomycin/administration&dosagecomparativestudydacarbazine/administration&dosagedoxorubicin/administration&dosagefollow-upstudieshodgkin'sdisease/KWDdrugtherapy/KWDetiology/pathologyhumanhivinfections/
921130
M92B0907

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .